I think Joe underestimated the effectiveness of the current vaccines (95%). There is also new research suggesting long term immunity to COVID for survivors. Joe suggests some theoretical off target risks with the current vaccines, however, no one seems to be experiencing these and the FDA hasn't raised and red flags. If current vaccines give long term immunity it REALLY diminishes the the case for Generex/NGIO. I'm going on the assumption current vaccines give long term immunity. That's not to say that there isn't opportunity abroad or in children. I can't see countries waiting until next summer/fall after the US is vaccinated. Personally, I'm starting to wonder about the value of GNBT sans COVID ... similar to GNBT's position last year (with a lot more shares in the wild).